[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"aortic-stenosis-with-bicuspid-valve\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:aortic-stenosis-with-bicuspid-valve":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,41,67],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100478578","down-sizing-strategy-hangzhou-solution-vs-standard-sizing-strategy-tavr-in-bicuspid-aortic-stenosis-type-0-100478578",false,"NCT05511792","Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)","Transcatheter Aortic Valve Replacement For Patients With Bicuspid Aortic Stenosis (Type 0) Using Down Sizing Strategy Compared With Standard Sizing Strategy (HANGZHOU Solution): A Prospective, Multicenter, Randomized Controlled Trial","TAILOR-TAVR","Inclusion criteria:\n\n1. Age ≥ 65 years;\n2. Age \\\u003C65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate (≥ 8%), Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment;\n3. Severe, bicuspid aortic stenosis: Mean gradient ≥40 mmHg OR Maximal aortic valve velocity ≥4.0 m\u002Fsec OR Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2); if SVi \\\u003C35mL\u002Fm2, low-dose dobutamine stress echocardiography is required;\n4. NYHA classification ≥ II;\n5. Type 0 (Sievers classification) by MDCT;\n6. Perimeter-derived annulus diameter ranges from 20.0 mm to 26.0 mm;\n7. Candidate for Transfemoral TAVR;\n8. The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)\u002FEthics Committee (EC) of the respective clinical site.\n\nExclusion Criteria:\n\n1. Any contra-indication for Self-expanding bioprosthetic aortic valve deployment Leukopenia (WBC \\\u003C 3000 cell\u002FmL), acute anemia (Hgb \\\u003C 9 g\u002FdL), Thrombocytopenia (Plt\\\u003C 50,000 cell\u002FmL).\n2. Active sepsis, including active bacterial endocarditis with or without treatment;\n3. Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \\[(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and\u002For troponin level elevation (WHO definition)\\].\n4. Stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure.\n5. Estimated life expectancy \\\u003C 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.\n6. Any Emergent surgery required before TAVR procedure.\n7. A known hypersensitivity or contraindication to any of the following that cannot be adequately medicated:aspirin or heparin (HIT\u002FHITTS) and bivalirudin; clopidogrel; Nitinol (titanium or nickel); contrast media\n8. Gastrointestinal (GI) bleeding that would preclude anticoagulation.\n9. Subject refuses a blood transfusion.\n10. Severe dementia (resulting in either inability to provide informed consent for the study\u002Fprocedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).\n11. Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams.\n12. Currently participating in an investigational drug or another device study (excluding registries).\n13. Hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with obstruction (HOCM).\n14. Echocardiographic evidence of intracardiac mass, thrombus or vegetation.\n15. Severe mitral stenosis amenable to surgical replacement or repair.\n16. Aortic valve type cannot be determined (Sievers classification).\n17. Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma \\[especially if thick (\\> 5 mm), protruding or ulcerated\\] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe\"unfolding\" and horizontal aorta(Annular Angulation\\>70°).\n18. Ascending aorta diameter \\> 50 mm.\n19. Aortic or iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath.\n20. Patient is considered high risk for TAVR by CT corelab, including coronary obstruction, annular rupture and other severe TAVR-Related complications.\n21. Previous pacemaker implantation.","ALL","60 Years",{"count":20,"type":21},206,"ESTIMATED","INTERVENTIONAL",[24],"NA","To compare down sizing strategy versus annular sizing strategy technique (control group) in Type 0 bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEVs): a randomized superiority trial",[27],"Aortic Stenosis With Bicuspid Valve","RECRUITING","2025-09-29",{"date":31,"type":32},"2025-10-03","ACTUAL",{"date":34,"type":32},"2022-06-27",{"date":36,"type":21},"2030-06-30",{"name":38,"class":39},"Second Affiliated Hospital, School of Medicine, Zhejiang University","OTHER",15,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":51,"studyType":52,"phases":4,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":66},"100504183","circle-method-observational-project---non-interventional-retrospective-multicenter-data-collection-100504183","NCT05844969","Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection","Circle Method Observational Project - Non-interventional, Retrospective, Multicenter Data Collection to Validate Circle Method for Sizing and Positioning in Bicuspid Aortic Valves","Inclusion Criteria:\n\n* Patients with bicuspid aortic valves who underwent aortic valve replacement with a balloon expandable valve (SAPIEN 3 \u002F Ultra)\n* Computed Tomography data available\n\nExclusion Criteria:\n\n\\- none","18 Years",{"count":50,"type":21},60,"12 Months","OBSERVATIONAL","The goal of this non-interventional, retrospective data analysis is to validate the circle method for patients with bicuspid aortic heart valves undergoing transcatheter aortic heart valve implantation (TAVI).\n\nThe main aims are:\n\n* to assess whether patients with bicuspid aortic valves that received a TAVI suffered from fewer complications\n\n  * if valve size was identical to the one determined using the circle method compared to\n  * a case where circle method derived valve size is different from the actually implanted valve\n* to develop recommendations on how to size the valve using the circle method.",[27],"NOT_YET_RECRUITING","2025-04-17",{"date":58,"type":32},"2025-04-22",{"date":60,"type":21},"2025-06-01",{"date":62,"type":21},"2025-08",{"name":64,"class":65},"Institut für Pharmakologie und Präventive Medizin","NETWORK",4,{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":22,"phases":76,"briefSummary":77,"conditions":78,"keywords":80,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},"100417983","hangzhou-solution-in-bicuspid-as-undergoing-tavr-100417983","NCT04722796","HANGZHOU Solution in Bicuspid AS Undergoing TAVR","HANGZHOU Solution for Patients With Bicuspid Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement by Using Supra-annular Structure Based Balloon Sizing Strategy","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Age \\\u003C65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate, Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment;\n* Severe, bicuspid aortic stenosis:\n* Mean gradient ≥40 mmHg\n* Maximal aortic valve velocity ≥4.0 m\u002Fsec\n* Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2\u002Fm2)\n* NYHA classification ≥ II;\n* Type 0, type 1 (Sievers classification) by MDCT\n* Perimeter-derived annulus diameter ranges from 20.0 mm to 29.0 mm;\n* Transfemoral TAVR\n* The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)\u002FEthics Committee (EC) of the respective clinical site.\n\nExclusion Criteria:\n\n* Any contra-indication for Self-expanding bioprosthetic aortic valve deployment\n* Leukopenia (WBC \\\u003C 3000 cell\u002FmL), acute anemia (Hgb \\\u003C 9 g\u002FdL), Thrombocytopenia (Plt\\\u003C 50,000 cell\u002FmL).\n* Active sepsis, including active bacterial endocarditis with or without treatment;\n* Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment \\[(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and\u002For troponin level elevation (WHO definition)\\].\n* Stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure.\n* Estimated life expectancy \\\u003C 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease.\n* Any Emergent surgery required before TAVR procedure.\n* A known hypersensitivity or contraindication to any of the following that cannot be adequately medicated:aspirin or heparin (HIT\u002FHITTS) and bivalirudin, clopidogrel,Nitinol (titanium or nickel),contrast media\n* Gastrointestinal (GI) bleeding that would preclude anticoagulation.\n* Subject refuses a blood transfusion.\n* Severe dementia (resulting in either inability to provide informed consent for the study\u002Fprocedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits).\n* Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams.\n* Currently participating in an investigational drug or another device study (excluding registries).\n* Hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with obstruction (HOCM).\n* Echocardiographic evidence of intracardiac mass, thrombus or vegetation.\n* Severe mitral stenosis amenable to surgical replacement or repair.\n* Aortic valve type cannot be determined (Sievers classification).\n* Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma \\[especially if thick (\\> 5 mm), protruding or ulcerated\\] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe\"unfolding\" and horizontal aorta(Annular Angulation\\>70°).\n* Ascending aorta diameter \\> 50 mm.\n* Aortic or iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath.\n* Patient is considered high risk for TAVR by CT corelab, including coronary obstruction, annular rupture and other severe TAVR-Related complications.\n* Previous pacemaker implantation.",{"count":75,"type":21},508,[24],"To compare supra-annular sizing and THV implantation technique (Hangzhou solution) versus annular sizing and THV implantation technique (control group) in bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEVs): a randomized superiority trial",[79,27],"Aortic Stenosis",[81,82,83],"Transcatheter aortic valve replacement","Aortic Stenosis with Bicuspid Valve","supra-annular sizing","2021-05-28",{"date":86,"type":32},"2021-06-02",{"date":88,"type":32},"2021-04-12",{"date":90,"type":21},"2028-04-01",{"name":38,"class":39},18]